EXEL: Zanzalintinib advances as a multi-indication franchise amid strong cabozantinib growth and targeted AI use
China-originated innovation and policy risks are shaping strategy, with a focus on novel assets and targeted AI use. Cabozantinib's growth and exclusivity are defended, while zanzalintinib is poised for multi-indication expansion. Early pipeline decisions are data-driven.Based on Exelixis, Inc. [EX…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.